CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
Authors
A Barbour
A Jemal
+50 more
A Paniccia
Alexander König
Andrea Tannapfel
Andreas Dickhut
Andreas W. Berger
Anke Reinacher-Schick
AS Zigmond
C Herrmann
CS Verbeke
D Cunningham
D Fitzsimmons
DD Hoff Von
DD Hoff Von
DD Stocken
DE Abbott
DS Zuckerman
Eike Gallmeier
F Huguet
G Butturini
H Haeno
H Oettle
H Snady
Hana Algül
I Esposito
Jens Atzpodien
JF Lawless
JP Neoptolemos
JP Neoptolemos
JW Valle
Kai Wille
L Rahib
Lukas Perkhofer
M Suker
Marko Kornmann
Michael Geissler
Nicole Prasnikar
NK Aaronson
R Alvarez
R Wilkowski
Rainer Muche
S Gillen
S Heinrich
S MacKenzie
Severin Daum
T Conroy
T Seufferlein
Thomas J. Ettrich
Thomas Seufferlein
Uwe Wittel
Waldemar Uhl
Publication date
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 11/12/2019